Drug Profile
Research programme: plectasin antibacterial - Sanofi
Alternative Names: NZ 2114; Plectasin derivative - SanofiLatest Information Update: 22 Jan 2014
Price :
$50
*
At a glance
- Originator Novozymes A/S
- Developer Novozymes A/S; Sanofi
- Class Peptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gram-positive infections
Most Recent Events
- 22 Jan 2014 Discontinued - Preclinical for Gram-positive infections in France (IV)
- 17 Aug 2012 Final pharmacodynamics and pharmacokinetics data from a preclinical study in Gram-positive infections released by sanofi-aventis
- 27 Oct 2011 Discontinued - Preclinical for Gram-positive infections in Denmark (IV)